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Background: Mycobacterium tuberculosis is characterized by a low mutation rate and a lack of genetic recombination.
Yet, the rise of extensively resistant strains paints a picture of a microbe with an impressive adaptive potential. Here we
describe the first documented case of extensively drug-resistant tuberculosis evolved from a susceptible ancestor
within a single patient.
Results: Genome sequences of nine serial M. tuberculosis isolates from the same patient uncovered a dramatic
turnover of competing lineages driven by the emergence, and subsequent fixation or loss of single nucleotide
polymorphisms. For most drugs, resistance arose through independent emergence of mutations in more than
one clone, of which only one ultimately prevailed as the clone carrying it expanded, displacing the other clones
in the process. The vast majority of mutations identified over 3.5 years were either involved in drug resistance or
hitchhiking in the genetic background of these. Additionally, RNA-sequencing of isolates grown in the absence of drug
challenge revealed that the efflux-associated iniBAC operon was up-regulated over time, whereas down-regulated
genes include those involved in mycolic acid synthesis.
Conclusions: We observed both rapid acquisitions of resistance to antimicrobial compounds mediated by individual
mutations as well as a gradual increase in fitness in the presence of antibiotics, likely driven by stable gene expression
reprogramming. The rapid turnover of resistance mutations and hitchhiking neutral mutations has major implications
for inferring tuberculosis transmission events in situations where drug resistance evolves within transmission chains.Introduction
The evolution of drug resistance is a major impediment to
current anti-tuberculosis efforts. Despite the low in vitro
mutation rate of Mycobacterium tuberculosis [1,2], cases
of extensively drug-resistant tuberculosis (XDR-TB) are
now frequently reported [3,4]. Multidrug-resistant tuber-
culosis (MDR-TB) is defined as isolates resistant to at least
the first-line drugs isoniazid (INH) and rifampicin (RIF),
whereas XDR-TB requires an MDR phenotype with
additional resistance to any fluoroquinolone (FLQ) and at
least one of the second-line injectable drugs capreomycin
(CPR), kanamycin (KAN or amikacin (AMK) [5]. By the
end of 2011, 77 countries had reported at least one case of* Correspondence: v.eldholm@gmail.com
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unless otherwise stated.XDR-TB, and about 9% of the approximately 650,000
MDR-TB cases worldwide qualified for XDR-TB status
[6]. Evidence of ongoing transmission of XDR-TB and so-
called totally resistant strains [3] makes the situation all
the more grave.
Emergence of drug resistance is generally attributed to
poor patient compliance with the standard multi-drug
regimen, yet the stepwise evolution of drug resistance
despite stringent adherence to a directly observed treat-
ment (DOT) protocol has been reported in a HIV co-
infected mining community [7]; in fact, the introduction
of the DOT and DOT plus programs in the absence of
drug susceptibility testing (DST) might have been instru-
mental for the evolution of XDR-TB [8]. Adding to this,
clinical trial simulations with a hollow fiber tuberculosis
(TB) model demonstrated that approximately 1% of TB
patients with perfect adherence would still develop MDR-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gence of drug resistance is a stepwise process and the evo-
lution of MDR-TB from a susceptible isolate or from
MDR-TB to XDR-TB in a single patient is not entirely un-
common (for example, [10-12]).
Here we report a detailed investigation of what to our
knowledge is the first published case of XDR-TB evolved
from a susceptible ancestor in a single patient, highlight-
ing the impressive adaptive potential of M. tuberculosis.
We analyzed the genomes of nine consecutive M. tuber-
culosis isolates from the same patient, recovered over a
42 month period (Figure 1), and found that resistance
mutations were acquired multiple times by individual
clones. The strain developed resistance to INH, RIF,
streptomycin (STR), FLQ, ethionamide (ETH) and AMK
as well as low-level resistance to ethambutol (EMB). Sur-
prisingly high genetic divergence was detected between
isolates collected over short time spans, reflecting the
rapid expansion and collapse of different clones evolving
in parallel. Finally, RNA-sequencing revealed that tran-
scriptional regulation of drug efflux and mycolic acid
synthesis may be involved in increased growth efficiency
in the presence of antibiotics.
Results and discussion
Microevolution of M. tuberculosis serial isolates
The genomes of the nine clinical isolates from the same
patient, representing various levels of phenotypic drug
resistance, from susceptible to XDR-TB were sequenced
at a median depth of 210× coverage. We applied SNP-
calling parameters appropriate for the detection of mul-
tiple clones present in any given clinical isolate. Over
the course of 42 months from diagnosis, we identified
35 mutations with a SNP frequency of >25% in at leastFigure 1 Time-line of clinical interventions and drug resistance acqui
indicate available clinical isolates. Above the dashed lines, the first instance
clinical isolates are indicated. The mutations are colored to match the drug to
ultimately fixed (>85% of reads in SF9), whereas non-boxed mutations indicat
EMB, ethambutol; STR, streptomycin; OFX, ofloxacin; ETH, ethionamide; CFZ, c
GFB, gemfibrozil; IFNγ, gamma interferon; CPR, capreomycin; LZD, linezolid. Frone isolate (Additional file 1), of which 20 were transient
and 15 went to fixation. Twenty-four mutations reached
a frequency of >70% in least one isolate, which is a more
typical threshold for SNP calling. Among the full set of
35 mutations, 12 could be assigned a role in conferring
drug-resistance (Table 1).
Phenotypic resistance to INH, RIF, FLQ, AMK and ETH
perfectly overlapped with the emergence of corresponding
known or high-probability resistance-conferring mutations
(Figure 2). For STR, however, predictions of drug resist-
ance from the genomic data contradicted the phenotypic
drug resistance profiling in one of the serial isolates which
had been typed as susceptible. This isolate (SF4) harbored
a gid nonsense mutation introducing a stop at codon 37.
Disruption of gid and its 16S RNA-methylase activity is
associated with low-level STR resistance [18]. We re-
tested the isolates for STR susceptibility and found that
isolate SF4 was indeed STR resistant, but grew less effi-
ciently when challenged with STR than subsequent iso-
lates harboring the rrs A514C mutation (Figure 3). The
last four isolates (SF6 to SF9) were originally typed as
EMB resistant, but re-testing did not confirm this. At a
lower EMB concentration (2 μg/ml versus 5 μg/ml),
however, we found that the last three isolates, harboring
non-synonymous embB mutations, did indeed grow well,
whereas the other isolates did not (Figure 3).
The isolates in the current study never evolved resistance
to pyrazinamide (PZA), despite continuous treatment over
3.5 years. Simulations built on an in vitro pharmacokinetic-
pharmacodynamic model of TB found that the currently
recommended PZA dosage (15 to 30 mg/kg body weight/
day) would result in sterilizing minimum inhibitory con-
centration in only 15.1 to 53.3% of patients [22]. It is thus
possible that pharmacokinetic factors could explain thesition. Drug regimen is indicated by horizontal bars. Black dashed lines
s of resistance-conferring mutations identified in the corresponding
which it confers resistance. Black boxes indicate mutations that were
e transient mutations. INH, isoniazid; RIF, rifampicin; PZA, pyrazinamide;
lofazimine; AMK, amikacin; AMC, amoxicillin/clavulanate; LVX, levofloxacin;
ameshift mutations are denoted as fs.
Table 1 Resistance mutations acquired over time in serial
isolates from patient
Gene Protein/RNA change Resistance Reference
gyrB S447F FLQ [13]
gyrB T500N FLQ [14]
mshA V238 frameshift ETH [15]
mshA A342E ETH [15]
rpoB S450L RIF [16]
rrs A514C STR [17]
gid G37 Stop STR [18]
rrs A1401G AMK/KAN [19]
katG W300R INH [20]
katG P7 frameshift INH [21]
embB N644I EMB
embB D1024N EMB
Mutations eventually reaching fixation are highlighted in bold.
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CPR were also used together with PZA towards the end of
the therapy, and failed to clear the infection despite contin-
ued susceptibility to these drug as deemed by DST. By the
time these drugs were added to the drug regimen, the pa-
tient had developed cavitary TB, a disease state known to
be associated with treatment failure [23], presumably dueFigure 2 Frequency of resistance mutations in serial isolates. (A) Frequ
background shading indicates that the isolate was resistant to the given drug o
the exception of EMB where the shading indicates resistance at 2 μg/ml on the
were resistant to both ofloxacin and ciprofloxacin. (B) PCR verification of selecteto reduced penetration of drugs in cavities [24]. The develop-
ment of cavitary TB over the course of infection has most
certainly played a role in rendering the infecting strain ex-
tremely resilient to antibiotic challenge. Addition of linezolid
to the regimen, a drug that has been shown to be effective
against cavitary MDR-TB [25,26], finally cleared the infection.
For five out of seven drugs to which the bacillus devel-
oped resistance, two independent resistance-conferring
mutations emerged, ultimately resulting in fixation of one
of the two mutations (Figures 2 and 4B). Only RIF (rpoB
S450L) and AMK (rrs A1401G) resistance were found to
result from a single mutation; in both instances the
resistance-conferring mutation was among the most
commonly observed, and the rpoB S450L mutation has
previously been shown to carry little or no fitness cost [27].
Extended DST following development of an MDR
phenotype revealed that all isolates were resistant to para-
aminosalicylic acid (PAS), but as this drug is not part of
the standard anti-TB drug regimens nor relevant to the
WHO’s definition of MDR and XDR, we refer to the initial
isolate (SF1) as susceptible. To place the serial isolates
in phylogenetic context and to identify mutations that
could be responsible for the pre-existing PAS resistance
common to all isolates, we identified single nucleotide vari-
ants in a published global collection of M. tuberculosis
lineage 4 isolates as well as the patient isolates. The analysisency of resistance mutations in sequencing reads from serial isolates. Grey
n the BD BACTEC 460 platform using standard critical concentrations, with
BD MGIT 960 platform (see main text for details). The FLQ resistant isolates
d resistance mutations, separated and visualized on agarose gel.
Figure 3 Growth efficiency in the presence of antibiotics of clinical isolates harboring different resistance mutations. Growth in
antibiotics relative to untreated controls (from the left: INH, STR, EMB). See main text for details. Color shading indicates the specific resistance
mutation present in each isolate. Isolate SF8 contains a mixture of two populations with two different embB mutations.
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struct a maximum likelihood tree (Figure 4A; Figure S1 in
Additional file 2; Additional file 3). Next, we investigated all
non-synonymous SNPs to identify mutations that could be
involved in drug resistance in this patient. Among 94 non-
synonymous SNPs unique to the patient isolates (Additional
file 3), we found a thyA P17L mutation that could explain
the observed PAS resistance [28]. Interestingly, the patient
isolates also harbored a unique uvrB A582V mutation. In
Escherichia coli, the Uvr(A)BC complex is responsible for
excision of a wide variety of DNA lesions. The uvrB A582V
mutation is localized in a region which in the E. coli
homologue displays binding affinity towards both UvrA and
UvrC [29], and could potentially lead to a reduction in DNA
repair capability in the patient isolates.
Increased fitness in the presence of antibiotics drives
clonal expansions
To investigate whether fitness in the presence of antibi-
otics was driving the expansion of successful clones atFigure 4 Intra-patient evolution and mutation rates. (A) Phylogenetic p
from a global M. tuberculosis collection (46). A thyA P17L mutation possibly co
on the branch leading to the patient isolates. sSNP, synonymous SNP. (B) Det
mapped on the branches. (C) Example of hitchhiking SNPs. Frequency of SNP
over time (months) as well as hitchhiking SNPs (grey shading) with correlation
plot of calculated pairwise mutation rates per year between any pair of isolate
II, resistance mutations excluded; Set III, resistance mutations and hitchhikingthe expense of disappearing clones, we assayed growth
efficiency of the isolates at a fixed concentration of anti-
biotics relative to untreated controls for each sample.
Challenged with INH and STR, isolates carrying the ul-
timately fixed INH or STR resistance mutation grew sig-
nificantly better than isolates harboring the transient
mutation, clearly indicating that increased fitness in the
presence of antibiotics was driving the expansion of indi-
vidual clones (Figure 3). For EMB, the picture was similar,
but complicated by the fact that EMB treatment was dis-
continued prior to fixation of any resistance-conferring
SNP. The embB D1024N mutation was present in almost
5% of the reads in SF7 and was ultimately fixed in SF9.
Interestingly, SF8 grew better than SF9 in EMB, indicating
that the transient embB N644I mutation conferred a
higher fitness in the presence of low concentrations of
EMB relative to embB D1024N. As EMB treatment was
discontinued prior to fixation of either mutation, this
probably indicates that the embB D1024N mutation im-
parts a lower fitness cost in the absence of drug challenge,lacement of patient isolates relative to the most closely related isolates
nferring para-aminosalicylic acid (PAS) resistance was acquired some time
ailed phylogeny of patient isolates with resistance-conferring mutations
s conferring resistance to FLQ (gyrB) and ETH (mshA) in sequencing reads
coefficients >0.9 relative to any gyrB or mshA resistance SNP. (D) Box
s using three different SNP exclusion criteria: Set I, all SNPs included; Set
SNPs excluded.
Eldholm et al. Genome Biology 2014, 15:490 Page 5 of 11
http://genomebiology.com/2014/15/10/490and was thus driven to fixation in the population following
removal of EMB from the treatment scheme. EMB suscep-
tibility testing has repeatedly been shown to be challenging
[30,31]. The embB D1024N mutation has previously been
described in one isolate characterized as EMB susceptible
[32]. However, our results indicate that this mutation con-
fers low-level EMB resistance, illustrating that characteriz-
ing resistance mutations conferring borderline resistance
remains problematic in a clinical setting. Intriguingly, iso-
lates harboring the same resistance mutations also differed
in growth efficiency in the presence of INH and STR, with
a clear trend of increasing fitness (Figure 3).
Recent studies have documented the presence of transient
genotypes and multiple concomitantly occurring drug-resist-
ance mutations in serial M. tuberculosis isolates [11,33,34].
However, our results allowed for an even finer characterization
of within-patient microbial dynamics than previous studies
thanks to the large number of serial isolates. Taken together,
these results point to 'battles among clones' being central to
the evolution of drug-resistant M. tuberculosis. Clonal expan-
sions seem driven by the increased fitness of mutant strains in
the presence of antibiotics relative to the clones they replace.
Mutation rates are inflated by drug-induced selection
In a recent study of longitudinalM. tuberculosis isolates, in-
cluding all the major lineages, the substitution rate was esti-
mated to 0.5 SNPs per genome per year (95% confidence
interval (CI) 0.3 to 0.7) and the divergence was rarely found
to be higher than five SNPs per three years [35]. In another
study of transmission chains the substitution rate was
found to be 0.4 mutations per genome per year [36]. After
exclusion of transient mutations in the patient isolates, 4.3
mutations were acquired per year from SF1 to SF9, or 2.3
mutations per year when excluding resistance mutations.
Antibiotic-induced expansion of resistant clones could po-
tentially distort mutation rate estimates as random SNPs in
the genetic background of resistant clones sweep to fixation
together with the resistance mutation. Our data set allowed
us to directly test for this possibility, as a large number of re-
sistance mutations emerged over time and as the frequency
of all identified SNPs were known over nine time points. We
plotted SNP frequencies over time, from which it became
apparent that SNPs not involved in resistance were changing
in frequency in concert with the resistance mutation. These
SNPs are located in the genetic background of expanding
and contracting drug-resistant clones and their frequency
changes over time closely mirror those of the resistance SNP
due to the absence of genetic recombination in M. tubercu-
losis (Figure 4C). We refer to such SNPs whose allele fre-
quency change is driven solely by linkage to a resistance
mutation under natural selection as hitchhiking SNPs.
To investigate the effect of drug-driven selective sweeps
on the substitution rate, we calculated pairwise SNP fre-
quency correlation coefficients for all SNPs together witheach of the 12 resistance mutations. Hitchhiking SNPs were
defined as SNPs not involved in resistance but present at
frequencies correlating closely (correlation coefficient >0.9)
with any one of the 12 identified resistance mutations over
the nine time points. Indels were excluded from these ana-
lyses, leaving only true SNPs. Subsequently, pairwise substi-
tution rates were calculated for all possible pairs of isolates,
a de facto simulation of a situation in which only two ran-
dom isolates would be available for study, which is the case
more often than not in a clinical setting.
Pairwise substitution rates were calculated for the follow-
ing SNP sets: I) including all SNPs; II) excluding resistance
mutations; and III) excluding resistance mutations and hitch-
hiking SNPs. The calculated mean pairwise substitution rates
were found to differ substantially between the three sets
(Figure 4D), with a mean mutation rate per genome per year
of 7.0 (95% CI 4.5 to 9.4) for set I, 4.3 (95% CI 2.4 to 6.1) for
set II and 1.1 (95% CI 0.7 to 1.6) for set III (Figure 4D), dem-
onstrating a massive influence of selection for resistance mu-
tations on substitution rates.
The existence of multiple clonal lineages within a single
patient has been well documented in recent reports
[11,33,34] and it has also been shown that the diversity of
M. tuberculosis isolates from a single patient can rival that of
different isolates from a transmission chain [33]. In the
current work we demonstrate that clinical M. tuberculosis
isolates descending from a single transmission event can in
fact reach a level of divergence within a patient that exceeds
the levels normally found between isolate pairs from a trans-
mission chain. Our findings demonstrate that SNPs hitch-
hiking with resistance mutations can drive a surprisingly
large number of SNPs to fixation over a short time span.
By coupling whole genome sequencing and epidemiological
information, a recent study found that 96% of paired isolates
differed by no more than five SNPs [35]. In the current study,
the most extreme SNP divergence over time was found be-
tween isolates SF5 and SF6, separated by only three months,
yet differing by 11 SNPs. It should be noted that most of the
SNPs differentiating SF5 and SF6 were present in both iso-
lates, but the frequency of the SNPs changed dramatically
over the three months separating the isolates, reflecting the
rapid expansion and collapse of two different clones.
In a typical SNP-calling scheme, mutations at low fre-
quencies are not picked up, and if these were the only iso-
lates available from the patient, it might well have been
interpreted as an exogenous reinfection. However, based
on the analysis of nine serial isolates, we can safely con-
clude that the dominant clones in isolates SF5 and SF6
shared a common ancestor that existed in the very patient
they were isolated from. After removal of resistance muta-
tions as well as hitchhiking mutations, the total number of
mutations separating the nine isolates decreased from 24
to 4, a clear indication that antibiotics-induced selection
was the main driver of the observed diversification over
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that the rapid emergence of resistance is facilitated by
large populations within the host harboring considerable
standing variation (many variants at very low allele fre-
quency), which might not be picked up even when se-
quencing at >100× coverage.
Genes involved in mycolic acid synthesis and drug efflux
are differentially expressed among serial isolates
We selected four isolates, SF1, SF4, SF5 and SF6, for
RNA sequencing, as these represented the initial isolate,
as well as the isolates in which the main bulk of resist-
ance development took place. Hierarchical clustering of
total gene expression levels revealed that transcription
patterns roughly reflected the phylogeny of the isolates
(Figures 4B and 5A). Analyses of differential expression
were performed for SF4, SF5 and SF6 independently
with SF1 as the reference.
A total of 139 genes were found to be differentially regu-
lated between at least one of the later isolates (SF4, SF5
and SF6) and SF1 (Figure 5B; Additional file 4). None of
the mutations emerging over time in the clinical isolates
were located in genes or promoter regions of genes for
which significant differential transcription was observed,
demonstrating that differential expression was not directly
attributable to mutations in corresponding gene regions
(Additional files 1 and 4).Figure 5 Differential gene expression in serial isolates. (A) Hierarchical
expressed genes in SF4, SF5 and SF6 relative to SF1. (C) Hierarchical cluster
indicated by blue and red coloring, respectively). (D) Fold change of iniB eClusters of orthologous groups (COG) analyses were
carried out for up- and down-regulated genes (Table S1
in Additional file 2). In all the later isolates, significantly
down-regulated genes relative to SF1 were enriched for
the COG category 'Secondary metabolites biosynthesis,
transport and catabolism' (P-values of 0.057, 0.019 and
0.016, respectively, for SF4, SF5 and SF6 relative to SF1).
Among the down-regulated genes were pks13 and fadD32,
members of the pks13-fadD32-accD operon, encoding en-
zymes that are responsible for the final steps of mycolic
acid synthesis [37]. Down-regulation of this operon could
possibly be involved in adaptation to INH and ETH treat-
ment, both of which target steps in mycolic acid synthesis.
Transcription of iniA, a member of the iniBAC operon,
involved in drug efflux and previously shown to confer in-
creased resistance to both INH and EMB [38], was signifi-
cantly up-regulated in SF6 relative to SF1. To investigate
transcription levels of the iniBAC operon in more detail,
we assayed iniB expression by quantitative PCR, which
confirmed upregulation of the gene in SF4 to SF6 relative
to SF1 (Figure 5). Concomitant with iniBAC up-regulation,
we observed a slight down-regulation of lsr2, a known
negative regulator of iniBAC expression [39].
We observed an increase in growth efficiency over time
that was independent of the specific resistance-conferring
mutations (Figure 3). This trend was most striking when
the isolates were grown in the presence of INH and theclustering of total gene expression. (B) Venn diagram of differentially
ing of interesting genes and operons (high and low expression
xpression relative to SF1. qPCR, quantitative PCR.
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tional reprogramming serves as an additional layer for
boosting fitness in the presence of drugs. We did indeed
observe patterns of differential gene expression that could
be involved in a systemic adaptation to challenge with
multiple compounds, namely an upregulation of iniBAC
expression combined with the down-regulation of pks13
and fadD32, encoding proteins responsible for the final
steps of mycolic acid synthesis.
Down-regulation of mycolic acid synthesis could poten-
tially alleviate detrimental effects of accumulated inter-
mediaries upon inhibition in InhA. The isolates in which
pks13 and fadD32 were down-regulated harbored a katG
P7 frameshift mutation resulting in a premature stop
codon. However, katG has an alternative start codon in
position +76 in the same frame as the annotated start
codon. Inspection of RNA-seq reads aligned to the H37Rv
reference genome revealed that katG was transcribed in full
length also in the isolates harboring the frameshift mutation,
despite a rather steep decline in transcription levels down-
stream of the new stop codon (Figure S2 in Additional file 2).
It is thus plausible that some KatG activity remained to
activate INH. WhiB7 was previously found to orchestrate
a transcriptional response to diverse classes of antibiotics,
conferring increased drug tolerance [40]. Our results sup-
port a role of transcriptional responses in modulating drug
susceptibility. As RNA was isolated from bacteria grown
in the absence of antibiotics, this finding indicates that
stable transcriptional changes had taken place.
Another possible explanation for the increased fitness
in the presence of INH and STR over time could be a cu-
mulative effect of multiple mutations. An ahpC N126D
mutation was common to isolates SF5 to SF9 and might
have increased the resistance to INH conferred by the
katG frameshift mutation. Promoter mutations resulting
in ahpC overexpression have been linked to compensation
for loss of katG-associated catalase activity [41]. However,
the ahpC N126D mutation is located in the body of the
gene, and as gain-of-function mutations are rare, it seems
unlikely that this mutation played a significant role in
INH resistance or fitness compensation. It is also possible
that the rrs A1401G mutation conferring KAN/AMK
resistance could yield increased resistance to STR in
combination with the rrs A514C mutation. However,
this scenario also seems relatively unlikely as such an ef-
fect has never been reported despite these being com-
mon and well-studied mutations. We did not identify
other obvious candidate mutations that could explain
this trend. Recent in vitro studies have shown that the
efflux inhibitor verapamil potentiates the antitubercular
effect of bedaquiline and CFZ and that efflux contrib-
utes to the emergence of MDR-TB [42,43]. Our findings
suggest that drug efflux could be an important mechan-
ism effectuating drug resistance also within patients.Conclusions
The availability of nine serial isolates combined with
deep sequencing gave us unprecedented insights into the
dynamics of the emergence of drug resistance in M. tuber-
culosis. A surprisingly large number of SNPs were found
to differentiate serial M. tuberculosis isolates evolving re-
sistance to multiple drugs within a single patient. Most of
the mutations were either resistance SNPs or hitchhiking
SNPs in the genetic background of resistance mutations.
This finding has major implications for the reconstruction
of transmission chains between patients under treatment.
In particular, the large number of SNPs we detected be-
tween isolates sampled only a few months apart suggests
that using a simple threshold of a maximal number of mu-
tations between pairs of isolates to rule out direct trans-
mission may often be inaccurate.
Mutations underlying antibiotic resistance evolving over
the course of infection were easily identifiable. However,
over the course of infection, the M. tuberculosis isolates
exhibited increased fitness in the presence of antibiotics
that was independent of any obvious resistance-associated
mutations. We did, however, identify patterns of differen-
tial gene expression that could explain the observed sys-
temic adaptation to challenge by multiple compounds,
including an up-regulation of the efflux-associated iniBAC
operon over time. This observation suggests that drug ef-
flux could be an important mechanism effectuating drug
resistance within patients. Drugs targeting either drug
efflux or transcriptional regulators that coordinate the
response of M. tuberculosis to antimicrobial compounds
could thus prove valuable in combination with conven-
tional anti-TB drugs.
Materials and methods
Patient clinical information and phenotypic resistance
An immigrant from Eastern Europe was diagnosed with
non-cavitary pulmonary TB at an outpatient clinic in
Norway. M. tuberculosis isolates from sputum were sen-
sitive to the conventional TB drugs. The patient was
treated with a standard anti-tuberculous regimen con-
sisting of INH, RIF and PZA. It is not known if the pa-
tient received DOT at the time. After eight months live
bacilli were still isolated from the sputum, a cavity in the
right upper lobe had developed and by this time the pa-
tient had developed MDR-TB resistant to INH and RIF.
The patient was then transferred to Oslo University
Hospital where the patient received DOT. The treatment
was changed to STR and EMB in addition to PZA.
Ofloxacin (OFX) and ETH were added to the scheme
shortly after. During the following year tubercle bacilli
were not isolated from the patient. However, two years
after initiation of the first therapy regimen, M. tubercu-
losis was again isolated and had now acquired resistance
to STR, OFX, ciprofloxacin and ETH. STR, ETH and
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EMB were continued and AMK and CFZ were added to
the scheme. Three months later the bacterium had de-
veloped resistance to EMB and AMK, and thus fulfilled
the diagnosis of XDR-TB. These drugs were discontinued
and replaced with CPR, amoxicillin/clavulanate, levofloxa-
cin, gemfibrozil and interferon gamma-1b inhalations. The
three latter experimental drugs were discontinued after a
short period, leaving PZN, CFZ and CPR as the regimen.
The cavity in the right lung persisted and upper lung lob-
ectomy was performed on the infected lung but failed to
clear the infection. Finally linezolid was added to the ther-
apy and the sputum became culture-negative three weeks
later. A full pneumectomy was performed shortly after
due to massive chronic tissue damage.
Isolates and ethics approval
Ethics approval for this study was obtained from the
Norwegian Regional Ethics committee (reference num-
ber 2014/191). Primary sputum cultures were collected
at Oslo University Hospital Ullevål and final DST and
molecular epidemiological typing performed at the
Norwegian Institute of Public Health (NIPH). All isolates
were typed by IS6110 RFLP and 24-locus MIRU-VNTR
[44], both methods yielding nine identical profiles.
Drug susceptibility testing and growth experiments
DST was performed on the BD BACTEC 460 (BD Diag-
nostics) radiometric system with the following critical con-
centrations: 6 μg/ml STR, 0.2 μg/ml INH, 2 μg/ml RIF,
7.5 μg/ml EMB, 2.0 μg/ml OFX, 2.0 μg/ml ciprofloxacin,
5 μg/ml ETH, 100 μg/ml PZA, 4.0 μg/ml AMK, 4.0 μg/ml
KAN, 4 μg/ml PAS and 10 μg/ml CPR. Re-testing of STR
and EMB susceptibility was carried out on the BD
MGIT™960 fluorometric system with standard concentra-
tions: 1 μg/ml and 4 μg/ml for STR and 5 μg/ml for EMB.
To assay fitness under antibiotic challenge, experiments
were performed in triplicates with the following treat-
ments: no drug (control experiments); 1 μg/ml STR,
0.4 μg/ml INH or 2 μg/ml EMB. Colonies were picked
from solid Löwenstein-Jensen (LJ) medium, adjusted to
McFarland turbidity 0.5 and inoculated in MGIT tubes
following standard procedures. To quantify growth effi-
ciency under drug challenge, growth unit (GU) read-outs
of the corresponding drug-treated sample at the time
when the growth control reached 400 GU was used.
Genome sequencing and analysis
Genomic DNA was isolated from a full loop of colonies
growing on LJ medium using a Bacterial DNA Kit
(Omega Bio-tek, Norcross, Georgia, USA) following themanufacturer’s instructions with the following modifications.
A 20 minute incubation at 94°C to inactivate the bacteria
was added after resuspension of bacteria in TE buffer.
Lysozyme incubation was performed for 60 minutes at 37°C
followed by bead beating 3 × 6,800 rpm for 30 seconds in
Precellys Tough micro-organism lysing tubes in a Precellys
24 biological grinder (Bertin Technologies, Ampère,
Montigny-le-Bretonneux, France) Genomic DNA (500 ng)
was used to generate sequencing libraries. DNA was
fragmented with NEBNext dsDNA fragmentase (NEB,
Ipswich, Massachusetts, USA) for 45 minutes according to
the supplied protocol. Fragmented DNA was purified with
Agencourt AMPure beads and Illumina sequencing librar-
ies generated with the High Throughput Library Prepar-
ation Kit (KAPA Biosystems, Wilmington, Massachusetts,
USA) following the manufacturer’s protocol. Individual li-
braries were indexed with NEXTflex barcodes (Bioo [SIC]
Scientific, Austin, Texas, USA) and sequenced on both the
Illumina HiSeq and MiSeq platforms with 50 bp single
end and 150 bp paired-end run modes, respectively. Fastq
reads were aligned to the H37Rv genome with SeqMan
NGen (DNASTAR), resulting in a median coverage of
210× (189× to 246×).
We first called SNPs in SeqMan Pro (DNASTAR) that
were present at a minimum depth of 50 and at a mini-
mum frequency of 25% reads in any one sample. Second,
we re-called SNPs at these positions in all samples, allow-
ing for a SNP frequency as low as 4%. Fixed mutations
were defined as being present in ≥85% of the reads in the
final isolate (SF9). Only SNPs found at a frequency of >70%
in at least one sample were used to construct a neighbor-
joining phylogeny of SF isolates. In any isolate, variants
at these positions were called as SNPs if the frequency
was above 50%. For comparative genomic analyses of SF
isolates with a global collection of lineage 4 isolates
(Additional file 3), paired-end reads were downloaded
from the NCBI Short Read Archive (ERP001731). Reads
were aligned as above. SNPs were called using a haploid
Bayesian approach in SeqMan NGen with the following
thresholds: SNP% 95, depth 20, Q60. Repetitive regions
including PE/PPE genes and SNPs occurring at a distance
of 10 bp or less relative to these or each other were ex-
cluded from all analyses. A PhyML phylogeny was con-
structed using SeaView [45].
Selected SNPs were verified by mutation-specific PCR
using primers specifically amplifying either the wild-type
or mutant allele (Table S2 in Additional file 2). PCR was
performed on a Roche LightCycler® real-time PCR ma-
chine using KAPA SYBR FAST master mix (KAPA) and
20 ng template DNA in 20 μl PCR reactions with the fol-
lowing cycling parameters: preincubation 95°C 1 minute;
cycling 3 s at 95°C, 30 s at 70°C (Roche, Basel, Switzerland).
For each primer pair, thermal cycling was terminated
when the earliest amplification reaction was in late
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ethidium bromide-stained agarose gels.
RNA sequencing and analysis of gene expression
For each of the three replicates per isolate, a full loop of
bacterial colonies picked from solid LJ medium was re-
suspended in 1 ml Tri reagent (Sigma-Aldrich, St Louis,
Missouri, USA) in Precellys tubes. The bacteria were
bead-beaten twice at 6,800 rpm for 30 s and cooled on
ice between and after beating steps. After beating, 0.2 ml
of chloroform was added directly to the Precellys tubes,
vortexed and centrifuged at 12,000 × g for 15 minutes at
4°C. RNA was precipitated from the aqueous phase with
0.5 ml isopropyl alcohol, incubated at room temperature
for 10 minutes and centrifuged at 12,000 × g for 10 minutes
at 4°C. The RNA precipitate was washed once with 75%
ethanol, air dried and dissolved in 30 μl nuclease-free
water, followed by DNAse treatment of the RNA with the
DNA-free RNA kit (Zymo Research, Irvine, California,
USA). For each replicate, rRNA was partially depleted
from 3 μg RNA using the Ribominus Transcriptome Isola-
tion Kit (Invitrogen, Carlsbad, California, USA). Enriched
mRNA was purified on Zymo RNA Clean & Concentrator
columns (Zymo) and RNA-sequencing libraries con-
structed with NEBNext® Ultra Directional RNA Library
Prep Kit (NEB) and indexed with NEBNext multiplex
oligos for Illumina (NEB). Libraries were sequenced on
the Illumina HiSeq 2000 platform with 50 bp single end
run mode.
Reads were aligned to the M. tuberculosis H37rv refer-
ence genome in SeqMan NGen. BAM assemblies were
imported into QSeq (DNASTAR). Experiments were nor-
malized by assigning reads per kilobase template per mil-
lion mapped reads (RPKM) and scaled to have a common
mean. Significant differential expression was defined as
P <0.05 after adjustment for multiple testing using the
Benjamini-Hochberg false discovery correction. Comple-
mentary DNA was synthesized from RNA using a Proto-
Script II First Strand cDNA Synthesis Kit with random
primers (NEB) according to the manufacturer's instruc-
tions. cDNA diluted 1:5 was used as template in 20 μl re-
actions. The primers used for amplification of iniB and
rpoB are listed in Table S1 in Additional file 2. Standard
curve templates were generated by preparation of 10-fold
dilution series of pooled cDNA from all samples (un-
diluted to 10-4 dilution). Expression levels of iniB were
normalized to rpoB expression across samples. COG
analyses were performed using the TB database [46].
Data access
Sequence reads were deposited at the European Nucleotide
Archive with the following accession numbers: [EMBL:
PRJEB5899] (genome sequences) and [EMBL:PRJEB5865]
(RNA sequences).Additional files
Additional file 1: SNPs differentiating the nine clinical TB isolates.
Additional file 2: Supplementary Tables and Figures.
Additional file 3: Synonymous SNPs identified in the nine serial TB
isolates and isolates from a global collection of TB isolates and
non-synonymous SNPs unique to the serial isolates.
Additional file 4: Differentially regulated genes identified by
RNA-seq.
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